Differentiating separate primary lung adenocarcinomas from intrapulmonary metastases with emphasis on pathological and molecular considerations: Recommendations from the IASLC Pathology Committee.

Autor:	Chou TY; Department of Pathology and Precision Medicine Research Center, Taipei Medical University Hospital and Graduate Institute of Clinical Medicine, School of Medicine and Precision Health Center, Taipei Medical University, Taipei, Taiwan. Electronic address: tehying@tmu.edu.tw., Dacic S; Department of Pathology, Yale School of Medicine, New Haven, Connecticut., Wistuba I; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Beasley MB; Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York., Berezowska S; Department of Laboratory Medicine and Pathology, Institute of Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland., Chang YC; Department of Medical Imaging, National Taiwan University Hospital, Taipei, Taiwan., Chung JH; Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea., Connolly C; International Association for the Study of Lung Cancer, Denver, Colorado., Han Y; Department of Pathology, Shanghai Chest Hospital, Jiaotong University, Shanghai, China., Hirsch FR; Center for Thoracic Oncology, The Tisch Cancer Institute, New York, New York and Icahn School of Medicine, Mount Sinai Health System, New York, New York., Hwang DM; Sunnybrook Health Sciences Centre, Odette Cancer Centre, Ontario, Canada., Janowczyk A; Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia., Joubert P; Institut Universitaire de Cardiologie et de Pneumologie de Quebec - Université Laval, Quebec City, Canada., Kerr KM; Department of Pathology, Aberdeen University School of Medicine and Aberdeen Royal Infirmary, Aberdeen, Scotland., Lin D; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing) and Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, China., Minami Y; Department of Pathology, National Hospital Organization Ibarakihigashi National Hospital The Center of Chest Diseases and Severe Motor & Intellectual Disabilities, Tokai, Ibaraki, Japan., Mino-Kenudson M; Department of Pathology, Massachusetts General Hospital & Harvard Medical School, Boston, Massachusetts., Nicholson AG; Department of Histopathology, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust and National Heart and Lung Institute, Imperial College, London, United Kingdom., Papotti M; Department of Oncology, University of Turin, Torino, Italy., Rekhtman N; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Roden AC; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota., Thunnissen E; Amsterdam University Medical Center, Amsterdam, The Netherlands., von der Thüsen JH; Department of Pathology, Erasmus MC, Rotterdam, The Netherlands., Travis W; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Tsao MS; Department of Pathology, University Health Network and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada., Yatabe Y; Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan., Yeh YC; Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital and Department of Pathology, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan., Bubendorf L; Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland., Chang WC; Department of Pathology, Taipei Medical University Hospital and Taipei Medical University, Taipei, Taiwan., Denninghoff V; Molecular-Clinical Laboratory, University of Buenos Aires-National Council for Scientific and Technical Research (CONICET), Buenos Aires, Argentina., Fernandes Tavora FR; Department of Pathology and Forensic Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil., Hayashi T; Department of Human Pathology, Juntendo University Faculty of Medicine, Tokyo, Japan., Hofman P; Laboratory of Clinical and Experimental Pathology, Hôpital Pasteur, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France., Jain D; Department of Pathology, All India Institute of Medical Sciences, New Delhi, India., Kim TJ; Department of Hospital Pathology, Yeouido St. Mary's Hospital, College of Medicine, Catholic University of Korea, Seoul, Republic of Korea., Lantuejoul S; Université de Grenoble Alpes, Grenoble and Department of Pathology, Centre Leon Berard, Lyon, France., Le Quesne J; Beatson Cancer Research Institute, University of Glasgow, NHS Greater Glasgow and Clyde Glasgow, Glasgow, United Kingdom., Lopez-Rios F; Pathology Department, Hospital Universitario 12 de Octubre, Madrid, Spain., Matsubara D; Department of Pathology, University of Tsukuba, Tsukuba, Ibaraki, Japan., Noguchi M; Department of Pathology, Naritatomisato Tokushukai Hospital, Chiba, Japan., Radonic T; Department of Pathology, Amsterdam University Medical Center, Free University Amsterdam, Amsterdam, The Netherlands., Saqi A; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York., Schalper K; Department of Pathology and Medicine, Yale School of Medicine, New Haven, Connecticut., Shim HS; Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea., Sholl L; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Weissferdt A; Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston., Cooper WA; Royal Prince Alfred Hospital, NSW Health Pathology, Camperdown, NSW, Australia.
Jazyk:	angličtina
Zdroj:	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2024 Nov 21. Date of Electronic Publication: 2024 Nov 21.
DOI:	10.1016/j.jtho.2024.11.016
Abstrakt:	Introduction: With the implementation of low-dose computed tomography (LDCT) screening, multiple pulmonary tumor nodules (MPTN) are diagnosed with increasing frequency and the selection of surgical treatments versus systemic therapies has become challenging on a daily basis in clinical practice. In the presence of multiple carcinomas, especially adenocarcinomas, pathologically determined to be of pulmonary origin, the distinction between separate primary lung carcinomas (SPLCs) and intrapulmonary metastases (IPMs) is important for staging, management, and prognostication. Methods: We systemically reviewed various means that aid in the differentiation between SPLCs and IPMs explored by histopathologic evaluation and molecular profiling, the latter includes DNA microsatellite analysis, array comparative genomic hybridization, TP53 and oncogenic driver mutation testing and, more recently, with promising effectiveness, next-generation sequencing (NGS) comprising small- or large-scale multi-gene panels. Results: Comprehensive histologic evaluation may suffice to differentiate between SPLCs and IPMs. However, molecular profiling using larger-scale NGS typically provides superior discriminatory power, allowing for more accurate classification. Based on the literature review and expert opinions, we proposed a combined 4-step histologic and molecular classification algorithm for addressing MPTN of adenocarcinoma histology that encourages a multidisciplinary approach. It is also noteworthy that new technologies combining machine learning and digital pathology may develop into valuable diagnostic tools for distinguishing SPLCs from IPMs in the future. Conclusions: Although histopathologic evaluation is often adequate to differentiate SPLCs from IPMs, molecular profiling should be performed when possible, especially in cases with tumors exhibiting similar morphology. This manuscript summarized the previous efforts in resolving the current challenges and highlighted the recent progress in the differentiation methods and algorithms used in categorizing multiple lung adenocarcinomas into SPLCs or IPMs, which are becoming more and more critical in precision lung cancer management. (Copyright © 2024 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu